Article Text

PTU-106 Managing hepatitis c virus infection in prison – same disease, different barriers
  1. L Corless,
  2. Y Gao-Du
  1. Gastroenterology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK


Introduction Hepatitis C virus (HCV) is common in the prison population, with reported prevalence of up to 19%1. High rates of injecting drug use (IDU) coupled with in-prison sharing of needles, tattoo and shaving equipment are thought responsible. Incarceration is considered an ideal opportunity to treat “hard-to-reach” groups due to reduced alcohol/drug use, and lack of financial or geographical barriers to engagement. We have delivered a prison treatment service for several years, and sought to compare HCV management in this group (PC) with the standard outpatient setting (OC).

Method A retrospective cohort study was conducted of referrals from 2013–2016. Since all 5 prisons in our catchment area are male-only, we excluded females from the OC group. Data were anlaysed with regard to demographics, clinical assessment and access to treatment.

Results Demographics: 369 male patients were referred over 3 years (82 PC; 287°C). Median age was 40 (23-60) in PC and 44 (22-80) in OC. Genotype 1 was commonest in both groups (PC 40/82 [48.78%]; OC 134/287 [46.69%]), followed by genotype 3 (PC 29/82 [35.37%]; OC 93/287 [32.40%]). The vast majority acquired HCV via IDU (PC 74/82 [90.24%]; OC 234/287 [81.53%]). Rates of non-attendance were far higher than expected in PC, but still significantly lower than OC (16/82 [19.51%] vs. 90/287 [31.36%], p=0.0365). In several cases, prison notes documented patient unwillingness to enter treatment. Assessment: Almost all patients across both cohorts had appropriate blood testing performed (PC 78/82 [95.12%]; OP 275/287 [95.82%]). Non-invasive assessment of liver fibrosis was offered to all patients attending an appointment; but significantly fewer PC attended for scan (PC 36/82 [43.90%]; OC 169/287 [58.89%], p=0.01596). The disparity is partly explained by lack of an in-house prison Fibroscan until 2015, with poor attendance to hospital for elastography prior to that. Longstanding prison organisational issues were also felt to impact attendance, even within prison. Treatment: Despite significantly more OC being offered anti-viral therapy (PC 20/82 [24.39%]; OC 108/287 [37.63%], p=0.02), successful completion of treatment was more likely in the PC group, although this did not quite reach significance (PC 11/20 [55.00%]; OC 35/108 [32.41%], p=0.053).

Conclusion Prison-based management is associated with greater engagement and ultimately more successful for those commencing treatment than standard care. Non-attendance remains a major barrier, even in a controlled environment. Whilst poor organisation may have prevented some attendances, many were patient-driven indicating that reasons for non-attendance go beyond logistical issues. A greater understanding of these factors is required if eradication of HCV is to be achieved.


  1. . Addressing hepatitis C in prisons and other places of detention: Recommendations by NHS England2013

Disclosure of Interest None Declared

  • viral hepatitis

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.